CL2024002627A1 - Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor. - Google Patents

Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor.

Info

Publication number
CL2024002627A1
CL2024002627A1 CL2024002627A CL2024002627A CL2024002627A1 CL 2024002627 A1 CL2024002627 A1 CL 2024002627A1 CL 2024002627 A CL2024002627 A CL 2024002627A CL 2024002627 A CL2024002627 A CL 2024002627A CL 2024002627 A1 CL2024002627 A1 CL 2024002627A1
Authority
CL
Chile
Prior art keywords
aticaprant
depressive disorder
major depressive
amorphous
crystalline forms
Prior art date
Application number
CL2024002627A
Other languages
English (en)
Spanish (es)
Inventor
Schmidt Mark
Popova Vanina
Savitz Adam
Melkote Rama
C Drevets Wayne
Gopal Srihari
Pemberton Darrel
Lagishetty Chakradhar
Fernandes Philippe
Kezic Iva
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CL2024002627A1 publication Critical patent/CL2024002627A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024002627A 2022-03-07 2024-09-02 Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor. CL2024002627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263317475P 2022-03-07 2022-03-07

Publications (1)

Publication Number Publication Date
CL2024002627A1 true CL2024002627A1 (es) 2025-01-24

Family

ID=85706849

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002627A CL2024002627A1 (es) 2022-03-07 2024-09-02 Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor.

Country Status (14)

Country Link
US (3) US11998524B2 (cg-RX-API-DMAC7.html)
EP (1) EP4489747A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508051A (cg-RX-API-DMAC7.html)
KR (1) KR20240156409A (cg-RX-API-DMAC7.html)
CN (1) CN119156211A (cg-RX-API-DMAC7.html)
AU (1) AU2023232536A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254365A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002627A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024012158A2 (cg-RX-API-DMAC7.html)
IL (1) IL315409A (cg-RX-API-DMAC7.html)
JO (1) JOP20240197A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024010980A (cg-RX-API-DMAC7.html)
TW (1) TW202345796A (cg-RX-API-DMAC7.html)
WO (1) WO2023170550A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
ES2189759T3 (es) 1999-05-12 2003-07-16 Hoffmann La Roche Derivados de imidazoiacepina.
US20020052365A1 (en) 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
WO2003082832A2 (en) 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
PT2208727E (pt) 2002-09-19 2012-10-11 Lilly Co Eli Éteres diarílicos como antagonista do receptor opióide
WO2004080968A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
EP1606275B1 (en) 2003-03-07 2008-08-27 Eli Lilly And Company Opioid receptor antagonists
CN1890208A (zh) 2003-12-12 2007-01-03 伊莱利利公司 类鸦片受体拮抗剂
BRPI0417714A (pt) 2003-12-22 2007-03-20 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
JP2007528898A (ja) 2004-03-12 2007-10-18 イーライ リリー アンド カンパニー オピオイド受容体拮抗物質
AU2005222640A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
US7381750B2 (en) 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
US7378448B2 (en) 2004-03-15 2008-05-27 Eli Lilly And Company Diphenylether amide derivatives as opioid receptor antagonists
WO2005090303A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
PL2001456T3 (pl) 2006-04-04 2010-05-31 Emodys Gmbh Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
JP2010500372A (ja) 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
MX2009002527A (es) 2006-09-08 2009-03-20 Pfizer Prod Inc Derivados de eter diarilico y usos de los mismos.
US7709522B2 (en) 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
US20130303497A1 (en) 2010-08-05 2013-11-14 Conrig Pharma Aps Deuterated 5-ht1a receptor agonists
WO2013086496A2 (en) 2011-12-09 2013-06-13 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
US10377698B2 (en) 2015-03-30 2019-08-13 University Of Innsbruck Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production
WO2016191763A2 (en) 2015-05-28 2016-12-01 Georgetown University Use of methadone metabolites for treatment of anxiety and depression
EP3468540A4 (en) 2016-06-13 2020-03-18 Board Of Regents Of the University Of Texas System PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
EP3490542A4 (en) 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
AU2017325870B2 (en) 2016-09-16 2021-07-22 Research Traingle Institute Tetrahydroisoquinoline kappa opioid antagonists
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
DK3596069T3 (da) 2017-03-17 2022-08-01 Scripps Research Inst Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil
SG10201802129QA (en) 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US20190255036A1 (en) 2018-02-16 2019-08-22 Alexander Kariman Compound and method for reducing neuropathic pain and depression
US11820835B2 (en) 2018-03-23 2023-11-21 University Of Kansas Cyclic tetrapeptide analogs
US11491144B2 (en) 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
US11103171B2 (en) 2018-10-23 2021-08-31 BlackThor Therapeutics, Ine. Systems and methods for screening, diagnosing, and stratifying patients
US20200171025A1 (en) 2018-11-29 2020-06-04 Srinivasa Rao Parella Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
US11266627B1 (en) * 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
WO2022234457A1 (en) * 2021-05-04 2022-11-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
EP4489748A1 (en) 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant

Also Published As

Publication number Publication date
US20250325515A1 (en) 2025-10-23
CO2024012158A2 (es) 2024-09-30
US20230277499A1 (en) 2023-09-07
JOP20240197A1 (ar) 2024-09-05
TW202345796A (zh) 2023-12-01
US20240316003A1 (en) 2024-09-26
US12171743B2 (en) 2024-12-24
AU2023232536A1 (en) 2024-10-24
CN119156211A (zh) 2024-12-17
MX2024010980A (es) 2024-12-06
EP4489747A1 (en) 2025-01-15
CA3254365A1 (en) 2023-09-14
WO2023170550A1 (en) 2023-09-14
IL315409A (en) 2024-11-01
KR20240156409A (ko) 2024-10-29
US11998524B2 (en) 2024-06-04
JP2025508051A (ja) 2025-03-21

Similar Documents

Publication Publication Date Title
CO2024012158A2 (es) Formas polimórficas de aticaprant para usar en el tratamiento del trastorno depresivo mayor
CO2024007220A2 (es) Compuestos que contienen heteroátomos y usos de estos
CO2023018231A2 (es) Restos de administración terapéutica novedosos y usos de estos
ECSP20020410A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CL2023000943A1 (es) Formas cristalinas de un compuesto farmacéutico.
NI202000080A (es) Inhibidores de magl
CO2022000278A2 (es) Composiciones y métodos de tratamiento de una afección mediada por th2 usando prevotella
MX2021001558A (es) Inhibidores de itk de pirrolopirimidina.
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
MX2018014573A (es) Vacuna contra el virus del zika.
MX2019012884A (es) Terapia de combinacion.
CO6390111A2 (es) Productos sanguíneos deshidratados por aspersión y métodos para elaborar los mismos
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2016000530A1 (es) Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
MX2017015292A (es) Composicion para tratar lesiones cerebrales.
CL2021003317A1 (es) Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelícula.
EP3922264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
MX2024014419A (es) Peptidos y metodos para usar en el tratamiento del dolor
MX2024014578A (es) Regimenes de dosis para tratamiento de infeccion de dengue
MX2015015379A (es) Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.
CO2020014673A2 (es) Selección y uso de bacterias que apoyan la melatonina para reducir el cólico del lactante
CO2023013406A2 (es) Análogos de rifamicina en combinación con vancomicina y usos de los mismos
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.